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Penyelidikan & Pembangunan sebagai satu cara untuk menyampaikan dpatan rojek htanlpuan 
kepada pihak Univesiti) . 
The role of PPARy in tumourigenesis is controversial. The obj~ctive of this project 
was to ·determine whether the PPARy ligand, ciglitazone, could modulate cell 
growiti-and PPARy expression in the colonic carcinoma cell line, C0~0205. 
Measurement of LDH (lactate dehydrogenase) release was used to;quantify the 
cytotoxic effects of ciglitazone on COL0205 cells. Ciglitazone induced cell death .. 
in a time and concentration-dependent manner with ECso of 25 J..LM and complete 
cell death at about 70 J..LM concentration after 24 hrs treatment. Following 
treatment of COLO 205 cells with 25 J..LM ciglitazone, the levels of PPARy mRNA 
expressed was measured by real-time PCR whilst its protein level assessed by 
Western blotting. We observed that both the transcriptional (mRNA) and 
translational (protein) levels of PPARy were significantly reduced following 
ciglitazone treatment. The observation that PPARy ligands, could affect the 
growth of COL0205 cells indicate that PPARy plays an important role in the 
regulation of cell growth and cell death in colorectal cancer cells. 
Peranan PPARy dalam tumorigenesis masih kontroversial. Objektif projek ini .. 
adalah untuk mengenalpasti sama ada ligand PPARy, ciglitazone, boleh 
memodulasi pertumbuhan sel dan ekspresi PPARy dalam sel karsinoma kolon, 
COL0205. Pengukuran rembesan LDH (laktat dihidrogenase) digunakan untuk 
mengkuantifikasi tindakbalas sitotoksik ciglitazone ke atas sel COLO 205. 
Ciglitazone merangsang kematian sel bersandarkan masa dan kepekatan 
dengan kadar EC50 sebanyak 25 J..LM dan kematian sel sepenuhnya pad a 
kepekatan 70 J..LM selepas 24 jam. Dengan menggunakan 25 J..LM ciglitazone ke 
atas COLO 205, aras mRNA PPARy diukur dengan "real-time" PCR manakala 
aras protein diukur melalui kaedah pemblotan Western . Didapati kedua-dua aras 
transkripsi (mRNA) dan translasi (protein) PPARy berkurangan selepas dikultur 
dengan ciglitazone. Keupayaan ciglitazone menjejaskan pertumbuhan COL0205 
menunjukkan kemungkinan PPARy memainkan peranan dalam regulasi 
pertumbuhan dan kematian sel kanser kolon. 
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Transcriptional and translational expression of PPARy in the 
human colorectal cancer cell line, COLO 205 
Nik Soriani Yaacob 1 & Norazmi Mohd. Nor, 
Schpols of 1Medical and 2Health Sciences, USM Health Campus 
USM Short Term Grant (304/PPSP/613·1140) 
Introduction 
Peroxisome proliferator-activated receptors (PPARs) are ligand-dependent transcription 
factors of the nuclear hormone receptor superfamily that includes the receptor for steroid, 
retinoid and thyroid hormone. These nuclear receptors are characterised by their ability to 
bind to specific DNA sequences and, when activated by a ligand, PPARs regulate the 
expression of various genes and their functions (Auwerx 1999; Vamecq eta/., 1999). PPAR 
was first cloned from the mouse liver by lsseman and Green in 1990. The PPAR family 
consists of three distinct isoforms, namely PPARa, PPARB (or PPARf3) and PPARy. Each 
isoform is encoded by a separate gene (Tontonoz eta/. 1994). PPARy is further divided into 
the PPARy1, PPARy2, PPARy3 and PPARy4 isoforms (Sundvold and Lien, 2001) whereby 
PPARy2 has an additional30 amino acids at its N-terminus but is believed to have similar 
functions as those of PPARy1 (Sundvold eta/. 1995). PPARy3 is only found in humans and 
the expressed protein is identical to that of PPARy1 (Fajas eta/., 1998). PPARy is found 
mainly in adipocytes and cells of the immune system (Braissant et a/1996; Lemberger et a/ 
1996) and is involved in the regulation of adipogenesis, glucose metabolism and 
macrophage development and function (reviewed in Kersten eta/., 2000). 
PPARr and carcinogenesis 
Although it has long been known that PPARa ligands such as hypolipidaemic drugs cause 
hepatocarcinogenesis in rodents (Reddy and Chu 1996), the possible involvement of PPAR 
in human neoplasms has only recently emerged. PPARy has been shown to be expressed 
in human colon cancer (Sarraf eta/., 1998), prostate cancer (Mueller eta/., 2000) and breast 
cancer (Clay eta/., 1999) cell lines. However the involvement of PPARy activity in inducing 
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growth inhibition in such tumours have been contradictory. For example, it has previously 
been shown that PPARy can inhibit the proliferation of human colorectal carcinomas 
(Brockman eta/., 1998). In sharp contrast with this, however, was the report that activation 
of PPARy promotes the development of colon tumors in C57BU6J-APCMin/+mice (Lefebvre 
et at., 1998), a clinically relevant model for both human familial adenomatous polyposis and 
sporadic colon canc~r (Suet~/., 1992). Recent evidence suggests that PPARy ligands 
could have an anti-tumor effect in human$ as these compounds decrease cell growth and 
induce apoptosis in several malignant human cell types, including colorectal carcinomas 
(S~rraf eta/., 1998). Specific ligands of PPARy such as the antidiabetic thiazolidinediones 
(TZDs), natural fatty acid derivatives, non-steroidal anti-inflammatory drugs (NSAIDs) and 
certain polyunsaturated fatty acids have been identified (Palmer et a/., 1998). 
In agreement with the potential role of PPARy ligands for the treatment of cancer, our 
present study was aimed at observing the growth inhibition of the colorectal cancer cell line, 
COL0205 by the PPARy ligand, ciglitazone. This aim was slightly different from the original 
one proposed under this grant whereby the determination of both PPARa and PPARy 
expression by two colorectal cell lines, HT-29 and COL0205 was proposed. The change 
was necessary because the amount of funds approved was about 45% less than that 
requested and also based on current developments in this research area including the use of 
a more advanced technique of gene quantification, namely, using real time PCR. In addition, 
we propose to correlate these findings with the expression of the corresponding proteins by 
the cell line. 
Objective 
The objective of this study was to quantify the mRNA expression of PPARy1 in the colorectal 
cancer cell line, COLO 205, at various time points following treatment with a 
thiazolidinedione, using real-time PCR. For this purpose, an internal standard for PPARy1·~ 
was constructed. The transcriptional expression of this gene was correlated with the 
corresponding protein expression levels. 
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Methodology 
Maintenance of cells 
COLO 205 cells were maintained at 37°C in 5o/o C02 humidified atmosphere in RPM I 
medium supplemented with 1 Oo/o heat-inactivated fetal bovine serum (FBS), 100 U/ml 
penicillin and 1 00 mg/ml streptomycin and passaged every 2 to 3 days. The amount of FBS 
was reduced to 2o/o prior to treatment. 
Optimisation ot' cell concentration 
Near confluent COLO 205 cells in 75cm2 culture flaks were harvested and titrate·d by 10-fold 
serial dilution ( 1 03 - 1 05 cells/ml) across a 24-well tissue culture plate to determine the 
optimum number of cells for seeding. Cell-free supernatants were collected for LDH activity 
determination as cell growths reached 70% confluence as observed under an inverted 
microscope. A further 2-fold serial dilution was then performed to check which number of 
cells would give about 70-80% confluency after 24-48 h incubation. The optimal cell 
concentration for seeding was determined to be about 1 x 1 05 cells/mi. 
Cytotoxicity assay 
The lactate dehydrogenase (LDH) release cytotoxicity assay was performed using the 
Cytotoxicity Detection Kit {Roche, Germany) to establish the EC50 values. Briefly, cells were 
cultured in 24-well plates in the presence or absence of ciglitazone, at a concentration range 
of 2.5 to 100 J.lg/ml, in triplicates, and harvested at various time points (0 to 72 hrs). 
Maximum LDH release {high control) was determined by solubilising cells with Triton X-100 
{1% w/v). Spontaneous LDH release {low control) was also determined from cells incubated 
with medium alone. Cell-free supernatants were collected into 96-well plates for LDH assay 
by a reaction in which tetrazolium salt was reduced to a red formazan salt. The absorbance 
was then read at 492nm using a microtiter plate spectrophotometer. The mean absorbance 
for each treatment group was calculated and the results were expressed as o/o cytotoxicity 
[(experimental value lowm~trol)--!-(high-eontr-ol---tew-eentFaiH<-1-00])...-ECso-Values-wer:~-------
obtained as half-maximum-effect concentrations from the fitted curves. . .. 
Total RNA extraction and eDNA synthesis 
COLO 205 cells were cultured in an appropriate concentration of ciglitazone (based on the 
ECso value) in 25cm2 flasks for up to 72 hrs. The cells were harvested at various time points 
and lysed in an appropriate buffer. Total RNA was then extracted from each cell sample 
using RNeasy Minikit (Qiagen, USA) according to the manufacturer's instructions. The RNA 
integrity was confirmed by gel electrophoresis and RNA purity and concentration were 
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measured by spectrophotometry (Biophoto.meter; Eppendorf, Germany). The total RNA 
(between 1 to 3 J.LQ) was then reverse-transcribed into eDNA using RevertAid™ Pi Minus First 
Strand eDNA Synthesis kit (MBI Fermentas, USA) in the presence of oligo(dT)18 primer and 
murine-maloney leukemia virus (M-MuL V) reverse transcriptase in nuclease-free deionized 
water according to the manufacturer's instructions. The success of eDNA synthesis was 
initially verified by PCR using primers specific for 18s rRNA (Maxim Biotech) .. 
Real-time PCR 
The mRNA expression of PPARy1 was measured by a more advanced method of 
quantitation known as real-time PCR, instead of by competitive PCR as originally proposed. 
This was carried out using specifically designed primers and Taqman probes, employing the 
ABI7000 Sequence Detection System (Applied Biosystems, USA). A homologous internal 
standard was constructed for the quantitation of the PPARy1 gene. For this purpose, a 
specific fragment of the target gene was first amplified from a eDNA library of human 
adipose tissue (Maxim Biotech) by PCR with gene specific primers, cloned into a TOPO® 
vector (Invitrogen, USA) and transformed in E. coli competent cells to produce the 
recombinant plasmid, pNSY HG1 (Figures 1 and 2). 
The concentration of the homologous internal standard (pNSY HG1) stock solution was 
adjusted to 1 pmoi/J.LI. Ten-fold dilution series of the standard was performed to obtain the 
standard curves. Each amplification reaction was performed in a 96-well optical reaction 
plate with appropriate controls, in triplicates. The reaction was started at sooc for 2 min for 
optimal AmpErase® uracyi-N-glycosylase (UNG) enzyme activity. The temperature was 
increased to 95°C for 1 0 min to activate the AmpliTaq Gold enzyme, followed by 40 cycles 
of denaturation at 95°C for 15 sec and primer annealing and extension steps at 60°C for 1 
min each. 
W8$tem blotting 
The protein expression of PPARy in COLO 205 cells following treatment with the ciglitazone 
was detected by Western blotting. COLO 205 cells were cultured in 75cm2 flasks and cell 
lysates were prepared by cell lysis and centrifugation. The protein concentrations were 
determined using the Bio-Rad Protein Assay Kit (Bio-Rad, USA). The samples were then 
resuspended in loading buffer and subjected to SDS-PAGE. Following transfer of proteins 
onto nitrocellulose membranes, immunoblotting was carried out using anti-PPARy polyclonal 
antibody (Santa Cruz Biotechnology, USA) and peroxidase-conjugated streptavidin (Dako, 
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ADIPOSE TISSUE eDNA 
EcoRI 
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l 
EcoRI 
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Cloning of pNSY HG1 for the preparation of hPPARy1- internal 
standard 
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Figure 2: Preparation of PPARy1 internal standard for real•time PCR 
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Denmark). Detection of the target protein was then carried out using an enhanced 
chemiluminescence system (Amersham Biosciences, UK) according to the manufacturer's 
instructions. 
Statistical Analyses 
One-way ANOVA Bonferroni-Dunn test was used to determine the difference in mRNA 
.. expression levels. The· data were presented as mean± standard errrn:.mean (SEM) and 
p<0.05 is considered to be statistically significant. 
Results 
Figure 3 shows the time course LDH release (0 to 72 hrs) by COLO 205 cells treated with up 
to 1 00 J.LM ciglitazone. The EC50 values were obtained as half-maximum-effect 
concentrations from the frtted curves and the mean values are shown in Table 1. An EC50 
value of 30 J.LM was obtained following 24 hr exposure of the cancer cells to ciglitazone. 
Longer exposure times decreased the EC50 values. Exposure to ~1 OJ.LM ciglitazone caused 
<1 0% cytotoxicity to the tumour cells and the drug concentration of 75 J.LM had resulted in 
1 00% cell death in 24 hrs. The threshold concentration of ciglitazone for COLO 205 cells 
was estimated at 25 JlM (Figure 4 ). This concentration was hence used to treat the cells for 
further investigations. 
Figure 5 shows the amplification profiles of the PPARy1 gene in COLO 205 cells 
treated/untreated with 25J..lM ciglitazone and 1 0-fold dilutions of its homologous internal 
standard, pNSY HG1, using Real-time PCR. Ciglitazone had caused a significant decrease 
in PPARy1 mRNA levels in these cells following 6, 12, 18, 24, 36, 48 and 60 hrs incubation 
with the drug with more than 50% reduction observed as early as after 6 hrs (Figure 6). 
Unlike the changes in the mRNA levels, no significant reduction was observed in the .protein 
expression of PPARy1 in COLO 205 cells after 6 hrs of treatment with 25J.LM ciglitazone 
(Figure 7). Significant reduction in the protein levels occurred at least after 24 hrs of drug 
exposure. 
USM Short-term final report: PPAR in COLO 205 (NSY 2003} 7 
,/ 
I 
1/ / . 
% cytotoxicity 
.- 71 h 
48 h 
• 24 h 
• 12 h 
• 6h 
-a-- Oh 
0 25 50- 75 100-
Concentration of ciglitazone (J.LM). 
Figure a·: Cytotoxic potential· of ciglitazone on c·oLO 2os· cell line 
Cells were cultured in the presence of ciglitazone (2.5 to 100 JJM) in triplicates. Time 
course LDH release (0 to 72 hrs) by COLO 205 cells (1x105 cells/well) was measured in 
the culture supernatants using. the Cytotoxicity Detection Kit to establish the EC50 values. 
Maximum LDH release (high control) was determined by solubilising cells with Triton X-
1.00. (1% w/v). and spontaneous LDH release (low control) was. determined. from ·, 
untreated cells-. The absorbance was read at 492nm. The results- are expressed as. %. 
cytotoxicity [(experimental· value -low control}/ (high control-low· control} x 1-00]}. Data-
points represent the· mean ± so· of three independent experiments performed in 
triplicates each time. ECso values were obtained as hatf-maximum-effect concentrations 
from the fitted curves. 
Tabre f: EC50 val·ues (JlM} for COLO 205· ceu·nnes treated with ciglifazone 
TIME/hour 
6 12 24 48 72 
c·oLozos 45"±4.78 38±3.27 30± 1.70 26 ± 1".25 20± 1.63 
Data are given as mean :I SO· (N} n=3· 
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Effective concentrations (EC50) of Ciglitazone 
Determined On COLO 205 Cell Line 
50 
6 12 24 48 72 
Incubation time (h) 
Figure 4: Time-dependent changes of EC60 value for ciglitazone in COLO 
205 cells 
EC50 values are plotted against the incubation times to estimate the threshold 
concentration for ciglitazone in the COLO 205 cells. The threshold ECso value gives the 
drug concentration at which the rate of cell death equals the rate of cell growth. 
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(a) 
(b) 
'-'18 gil ~ }:~(:•:-::' 
__,_·;.::_ ··~ -~ ... 
Figure 5: Real-time PCR profiles (a) and standard curve of pNSY HG1 (b) 
Real-time PCR was performed on the eDNA samples obtained from cultured cells 
together with 10-fold ~ilutions of the pNSY HG1 (internal standard) for quantitation of 
PPARy1 mRNA levels 1n COLO 205 cells treated/untreated with 25 J.tM ciglitazone for 6 to 
72 hrs. All samples were run in triplicates 
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Figure 6: Effect of ciglitazone on PPARy1 mRNA expression in COLO 205 
cells 
Cells were treated with 25 11M ciglitazone for 6, 12, 18, 24, 36, 48, 60 and 72 hrs_ Gene 
expression was measured by quantitative real-time PCR using a homologous . internal 
standard. Data are expressed as mean±SE (n = 3 to 6). One way-ANOVA Bonferroni-
Ounn test was performed comparing the treated cultures (t) with the corresponding control 
cultures. p values of < 0.05 (*) and < 0.01 ** are considered si nifi.c..antly_different.------ ---
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Figure 7: Effect of ciglitazone on PPARy protein expression in COLO 205 
cells 
Cells were treated with 25 1-1M ciglitazone for 6, 12, 18, 24, 36, 48, 60 and 72 hrs. Cell 
lysates were prepared and electrophoresed on 10% SDS-PAGE (100 IJ.QIIane). Proteins 
from gels were transferred to PVDF membrane, and PPARy was detected with goat anti-
human PPARy polyclonal antibody, and visualised with enhanced chemiluminescence. 
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Discussion 
A homologous internal standard for real-time PCR quantitation of hPPARy1 was 
successfully produced and confirmed by DNA sequence analysis. The resulting recombinant 
plasmid, known as pNSY HG1, was used to prepare the standard curves for quantitative 
analyses of target eDNA samples. 
Measurement of LDH relea·se from.cells into the medium has been established as a useful 
.. ~ .... . . . -· 
parameter for tt1e measurement of cellular cytoxicity (Korzeniewski & Callewaert, 1983). 
This parameter was thus used in the current study to quantify the cytotoxic effect of the 
PPARy ligand (a thiazolidinedione class of drug), ciglitazone on COLO 205 cells that were 
established from a metastatic colonic adenocarcinoma. Ciglitazone had induced the 
colorectal cancer cell death in a time and concentration-dependent manner with EC50 of 25 
JlM and complete cell death at about 70 JlM concentration after 24 hrs treatment. This 
slowing or inhibition of tumour cell growth indicates the potential use of ciglitazone or other 
PPARy ligands as potential anti-tumour drugs. 
Conclusion 
The observation that PPARy ligands, could affect the growth of COL0205 cells indicate that 
PPARy plays an important role in the regulation of cell growth and cell death in colorectal 
cancer cells. This study may help to examine the therapeutic potential of PPARy ligands 
(natural or synthetic) for colorectal cancer. Elucidating the role of PPARs in the mechanism 
.• of tumourigenesis will pave the way for future establishment of an in vitro system that can be 
used for identification of sp~cific agonists or antagonists of these receptors among the local 
natural products that are currently used for the purported treatment of various conditions. 
Future studies should therefore include comparison of inhibitory effects of PPARy ligands on 
other types of colorectal cell lines, such as HT-29 cells that originate from a well-
, differentiated adenocarcinoma, compared to COLO 205 cells which are established from a 
metastatic colonic adenocarcinoma. 
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